OSE Pharma

OSE Pharma, Effimune to merge

Friday, February 26, 2016

OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration phase III study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, have announce the signing of a proposed merger agreement.

[Read More]

Demonsang, Tobelem join OSE Pharma board, Peyroles named CFO

Wednesday, November 13, 2013

OSE Pharma, dedicated to severe and orphan lung diseases, has announced the nomination of two new board members with a broad international experience and the recruitment of a CFO from the healthcare industry. These appointments are part of the plan to launch phase III of its targeted lung cancer immunotherapy product.

[Read More]